AKRO: Akero Therapeutics Inc

AKRO新闻

• 13:40 Has Akero Therapeutics (AKRO) Outpaced Other Medical Stocks This Year?
• 13:55 Does Akero Therapeutics (AKRO) Have the Potential to Rally 59.14% as Wall Street Analysts Expect?
• 15:13 RCKT Stock Rises as FDA Lifts Clinical Hold on Danon Disease Study
• 21:45 Akero Therapeutics: Reversing My Contrarian Buy Rating To A Contrarian Sell Rating (AKRO)
• 15:11 Allogene's Q2 Loss Narrower Than Expected, Pipeline in Focus
• 22:54 Akero Therapeutics CEO Cheng sells $1.46 million in stock
• 22:51 Akero Therapeutics COO Young sells $597k in shares
• 00:45 Akero therapeutics director Henderson sells $142k in shares
• 13:40 Are Medical Stocks Lagging Akero Therapeutics (AKRO) This Year?
• 14:54 Akero Therapeutics stock strengthened as Morgan Stanley reiterates Overweight rating
• 10:22 Janus Henderson Global Life Sciences Diversified ADR Managed Account Q2 2025 Commentary
• 18:36 Akero Therapeutics stock initiated with Buy rating at TD Cowen on MASH potential
• 18:35 Akero Therapeutics stock initiated with Buy rating at TD Cowen on MASH treatment potential
• 15:30 This AeroVironment Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Akero Therapeutics (NASDAQ:AKRO), Apartment Inv & Mgmt (NYSE:AIV)
• 10:20 Janus Henderson Global Life Sciences Fund Q2 2025 Commentary (Mutual Fund:JAGLX)
• 12:46 Altimmune Gears Up to Report Q2 Earnings: Here's What to Expect
• 16:10 Amarin Gears Up to Report Q2 Earnings: Here's What to Expect
• 15:42 Incyte Gears Up to Report Q2 Earnings: Is a Beat in the Cards?
• 14:45 VKTX Stock Down on Wider-Than-Expected Loss in Q2, Nil Sales
• 09:46 Altimmune: Potential Tough Road Ahead Amid Fierce Competition (Rating Downgrade) (ALT)
• 14:53 Exelixis' Q2 Earnings: Will Cabometyx Sales Drive Growth?
• 13:38 Viking Therapeutics Gears Up for Q2 Earnings: Here's What to Expect
• 15:28 RCKT Stock Up on FDA's RMAT Tag to Gene Therapy for Heart Failure
• 14:39 FDA Advisory Panel Votes Against Approval of GSK's Blenrep Combo